Let’s start with the good news. We are at the beginning of a transformation in human health, treating diseases in ways that we could only speculate about in the recent past. While biology isn’t quite engineering (yet), biotech has become a technology-based, high-growth, high-wage space, all while working to cure cancer. Doing well by doing … Continue reading “Innovation vs. Healthcare Spending: Biotech’s Biggest Looming Challenge”
Author: Jason Rhodes
Jason Rhodes is a partner at Atlas Venture focusing on the creation, development, and business strategy of novel therapeutics companies.
Jason is on the board of Replimune, Bicycle Therapeutics, and Raze Therapeutics. Prior to joining Atlas Venture in 2014, Jason was president and chief financial officer of Epizyme, where he was instrumental in charting the company’s strategic course and building the business towards a successful IPO in 2013. He established and was responsible for all business functions and led the company’s partnerships with Celgene, GSK, Eisai and others.
Prior to Epizyme, Jason was vice president of business development at Alnylam Pharmaceuticals, where he led corporate partnerships with companies including Takeda, GSK, Isis, Cubist, Roche, Kyowa Hakko Kirin, and Medtronic as well as the spin out of Regulus Therapeutics.
Before joining Alnylam, Jason was a founder and partner with Fidelity Biosciences, the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including Ironwood Pharmaceuticals, FoldRx (purchased by Pfizer), and Tetraphase Pharmaceuticals.
He is a member of the Berklee College of Music Presidential Advisory Council and the advisory board of the Institute of RNA Medicine at the Beth Israel Deaconess Medical Center.